Veru Inc. (NASDAQ: VERU) Q2 2022 earnings call dated May. 12, 2022 Corporate Participants: Samuel Fisch -- Executive Director of IR and Corporate Communications
Veru Inc. (VERU) Q2 2022 Earnings Call Transcript

Veru Inc. (NASDAQ: VERU) Q2 2022 earnings call dated May. 12, 2022 Corporate Participants: Samuel Fisch -- Executive Director of IR and Corporate Communications
Cara Therapeutics Inc. (NASDAQ: CARA) Q1 2022 earnings call dated May. 09, 2022 Corporate Participants: Iris Francesconi -- Interim Head of Investor Relations Christopher
Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than-expected earnings and revenues for the first quarter of 2022. The positive outcome
ImmunoGen, Inc. (NASDAQ: IMGN) Q1 2022 earnings call dated May. 06, 2022 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications Mark Enyedy -- President
Biogen Inc. (NASDAQ: BIIB) is currently going through a difficult phase as the biotechnology firm’s main products face stiff competition and the
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q1 2022 earnings call dated May. 04, 2022 Corporate Participants: Andrea N. Flynn -- Vice President, Head, Investor Relations
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q1 2022 earnings call dated May. 04, 2022 Corporate Participants: Ryan Crowe -- Vice President of Investor Relations Leonard
Moderna Inc. (NASDAQ: MRNA) Q1 2022 earnings call dated May. 04, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President and Head of Investor
Sage Therapeutics Inc. (NASDAQ: SAGE) Q1 2022 earnings call dated May. 03, 2022 Corporate Participants: Helen Rubinstein -- Investor Relations Barry Greene -- Chief Executive Officer
For Eli Lilly and Company (NYSE: LLY), 2021 was a fruitful year in terms of financial performance and product development. Reflecting the
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net income attributable
Eli Lilly and Company (NYSE: LLY) has reported higher earnings and revenues for the first quarter of 2022. The numbers also surpassed
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q1 2022 earnings call dated Apr. 27, 2022 Corporate Participants: Traci McCarty -- Vice President, Investor Relations Jean-Jacques Bienaime -- Chairman
Beyondspring, Inc. (NASDAQ: BYSI) Q4 2021 earnings call dated Apr. 14, 2022 Corporate Participants: Ashley Sierchio -- Investor Relations Lan Huang -- Co-founder, Chairman & Chief
The IPO market is yet to fully recover from headwinds like the economic slowdown and Russia-Ukraine war. But activity is gradually picking
Trxade Health Inc (NASDAQ: MEDS) Monday reported a narrower net loss for the fourth quarter of 2021 as the pharmaceutical services company's revenues
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Q4 2021 earnings call dated Mar. 17, 2022 Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer and
After starting the year on a high note, the IPO market is currently going through a slow phase mainly due to the
Bio-Path Holdings, Inc. (NASDAQ: BPTH) Q4 2021 earnings call dated Mar. 11, 2022 Corporate Participants: Will O'Connor -- Investor Relations Peter Nielsen -- President, Chief Executive
Avid Bioservices, Inc. (NASDAQ: CDMO) Q3 2022 earnings call dated Mar. 08, 2022 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President & Chief
Novavax, Inc. (NASDAQ: NVAX) Q4 2021 earnings call dated Feb. 28, 2022 Corporate Participants: Silvia Taylor -- Senior Vice President of Global Corporate Affairs